Minaris Regenerative Medicine’s leaders and experts are proud to share their knowledge and insight with the cell and gene therapy industry. Please review our current and past blog posts on topics of interest to this emerging industry.
The following is a guest blog by Kevin O’Donnell, Vice President, Cold Chain Standards, Practices & Compliance, BioLife Solutions As forecast by the White House 2012 ...
This is the second in a three-part series (Part 1 can be found here). As you enter this mid-phase of development, we reflect on these words from Albert Einstein: “In the ...
It is no secret that patient-specific cell therapies are widely perceived to be expensive to produce, which leads to expensive products, if they commercialize at all. I ...
If you’re reading this, you’ve no doubt already discovered that cell therapy manufacturing comes with its share of specific challenges, no matter what phase of ...
The following is an excerpt from an article published in the April issue of BioProcess international, entitled “Factories of the Future: Can Patient-Specific Cell ...
Like an army, cell therapy marches on its stomach, and good supply chain management can (literally) keep it fed. However, the “soldiers” of cell therapy are the most ...
If you’re a striker (playing forward position) on a soccer team, you know that your primary role is to score a goal. But what makes you confident in your ability to ...
The following is an excerpt from an article originally published in the October issue of BioProcess International, written by:
The following is an excerpt of a commentary originally published in the September issue of DDNews, entitled, “Building a Problem or a Solution? : Removing the ...